Mylan NV's defense of its price increases for EpiPen do not seem to have assuaged a number of members of Congress, but the real question may be how many Republicans believe the company should be the focus of their ire.
The chorus of Democrats calling for congressional scrutiny of Mylan's pricing of EpiPen (epinephrine), as well as its decision to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?